SHENZHEN, November 19, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”, 867. HK/8A8. SG) is delighted to reveal that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an ingenious pharmaceutical business concentrated on skin health which is requesting a different listing on the Main Board of The Stock Exchange of Hong Kong Limited), has actually registered the very first client in the China Phase III medical trial of its ingenious oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.
The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III medical research study assessing the effectiveness and security of povorcitinib in Chinese adult clients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the research study is prepared to be carried out at around 44 scientific proving ground throughout China and is anticipated to enlist around 174 clients with non-segmental vitiligo.
The Product has actually formerly finished a series of scientific trials associated with pharmacokinetics and bioequivalence in healthy individuals in China, and has actually been consisted of in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of individuals’s Republic of China (“NMPA”). This accreditation has the possible to accelerate its advancement and evaluation procedure. The registration of the very first client in this China Phase III scientific trial marks a critical phase in the Product’s medical advancement in China and lays a structure for additional assessing its effectiveness and security in Chinese clients with vitiligo.
Resolving Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options
Vitiligo is a persistent autoimmune illness defined by depigmentation of the skin. It is approximated that there are around 10.3 million vitiligo clients in China and non-segmental vitiligo clients represent roughly 8.2 million[1]Presently, treatment alternatives are restricted for vitiligo clients who need systemic treatment, and their scientific treatment requires stay improperly satisfied.
Overactivity of specific proinflammatory cytokines that indicate through the JAK-STAT path, is thought to drive swelling and add to the pathogenesis and development of vitiligo. Incyte has actually revealed that Phase III scientific research studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in grownups with non-segmental vitiligo have actually satisfied the main endpoints[2]If authorized in China, the Product has the possible to supply a brand-new oral treatment choice for clients with non-segmental vitiligo and, together with Dermavon’s commercialized ingenious drug Lumirix ® (ruxolitinib phosphate cream), offer vitiligo clients with detailed and varied treatment alternatives, from accurate topical intervention to systemic treatment.
Concentrating on significant skin illness such as vitiligo, atopic dermatitis and psoriasis, Dermavon has actually established an ingenious item portfolio covering various illness phases and scientific requirements. The registration of the very first client in the Phase III scientific trial of povorcitinib in China represents another crucial turning point in Dermavon’s improvement of regional scientific advancement for worldwide ingenious drugs. Moving forward, Dermavon will continue to take advantage of its strong international R&D collaborations and scientific advancement abilities in China to speed up the translation of development into medical application and bring more expert and distinguished treatment alternatives to clients with skin illness in China.
More Information About Povorcitinib Phosphate Tablets
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with substance and usage patents in specific countries/regions in the Territory. In addition to vitiligo, the Product has actually likewise shown advancement capacity in other indicators. Incyte is performing Phase III scientific trials of povorcitinib for the treatment of prurigo nodularis (PN) in a number of nations outside China, and has actually gotten European Commission approval for hidradenitis suppurativa (HS). Dermavon might likewise think about starting medical advancement of the Product in China for the treatment of extra skin-related illness.
A subsidiary of Dermavon participated in a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, getting a special license to research study, establish, sign up and advertise the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian nations (the “Territory”) and a non-exclusive license to make the Product in the Territory. The subsidiary of Dermavon has actually sublicensed the pertinent rights of povorcitinib in the Territory aside from Mainland China to China Medical System Holdings Limited (leaving out Dermavon and its subsidiaries).
About CMS
CMS is an ingenious pharmaceutical business concentrated on the recognition, structure, and complete lifecycle management of distinguished specialized pharmaceuticals. With a dual-engine method of internal R&D and collective R&D, and leveraging its core ability to construct markets and brand names from the ground up, the Group allows each medication to completely understand both its medical worth and business worth.
CMS has actually developed an end-to-end ability loop throughout the complete item lifecycle– specifically recognizing quality development targets, matching them with optimum advancement paths, and effectively advancing medical advancement and registration; establishing medical techniques lined up with scientific requirements, and driving scaled scientific adoption through an expert scholastic promo system and network.
CMS concentrates on advantaged specializeds consisting of cardiovascular-kidney-metabolic, main nerve system, gastroenterology, ophthalmology, and skin health. Through expert scholastic promo and scholastic resources throughout several illness locations, CMS has actually constructed sustainable scale benefits in specializeds, with its skin health company ending up being a leading gamer in its sector. CMS continues to reinforce its worldwide duplication abilities, confirming the transferability of its service design in emerging markets such as Southeast Asia and the Middle East, and injecting long-lasting momentum for the Group’s premium, sustainable advancement.
Referral
1. China Insights Consultancy (CIC) report
2. Public info on the Incyte authorities site: https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides
CMS Disclaimer and Forward-Looking Statements
This news release is not meant to promote any items to you and is not for marketing functions. This news release does not advise any drugs, medical gadgets and/or signs. If you need to know more about the medical diagnosis and treatment of particular illness, please follow the viewpoints or assistance of your medical professional or other medical and health specialists. Any treatment-related choices made by health care specialists must be based upon the client’s particular scenarios and in accordance with the drug plan insert.
This news release which has actually been prepared by CMS does not make up any deal or invite to buy or subscribe for any securities, and will not form the basis for or be counted on in connection with any agreement or binding dedication whatsoever. This news release has actually been prepared by CMS based upon info and information which it thinks about reputable, however CMS makes no representation or service warranty, reveal or suggested, whatsoever, and no dependence will be put on, the reality, precision, efficiency, fairness and reasonableness of the contents of this news release. Specific matters gone over in this news release might consist of declarations relating to the Group’s market chance and service potential customers that are separately and jointly positive declarations. Such positive declarations are not assurances of future efficiency and go through recognized and unidentified threats, unpredictabilities and presumptions that are tough to forecast. Any positive declarations and forecasts made by 3rd parties consisted of in this news release are not embraced by the Group and the Company is not accountable for such third-party declarations and forecasts.
Media Contact
Brand Name: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email:
Site: https://web.cms.net.cn/en/home/
Subject: Press release summary
Source: China Medical System Holdings Limited
Sectors: BioTech, Healthcare & & Pharm, MedTech, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights scheduled. A department of Asia Corporate News Network.
Discover more from PMN S.P.O.R.T.S - A PRIME MEDIA NETWORK BRAND
Subscribe to get the latest posts sent to your email.





